SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback